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Objectives
Cancer vaccines have promise as monotherapy or as part
of combination immunotherapy regimens. Age and gender
implications on immune response to cancer vaccinations
have not previously been well described. There is uncer-
tainty about including elderly patients as study participants
in vaccine trials because of the decline in immune
response with increasing age [1,2]. Compelling evidence
has also demonstrated gender differences in immune
response associated with injury and vaccination for infec-
tious diseases [3,4]. We hypothesized younger age and
female gender may be predictive of higher rates of
immune response to a multipeptide cancer vaccine. Data
collected from three clinical trials evaluating T cell
response to a polyvalent melanoma peptide vaccine pro-
vide an opportunity to assess the association of immune
response with age and gender.
Methods
Patients with resected stage IIB-IV melanoma were
enrolled in three clinical trials: Mel43, Mel44, and Mel48,
in which they received 6 vaccinations with 12 Class I
MHC restricted peptides from melanocytic differentiation
antigens and cancer testis antigens with each of various
adjuvants. T cell responses were detected by direct IFN-
gamma ELIspot assay. Clinical data, including age and
gender, were collected. The cumulative incidence in
immune response over time was plotted for each variable.
Chi-squared analysis was performed on the number of
immune responders by age and gender.
Results
A total of 327 patients were evaluated for immune
response measurable by Week 7. Immune responses
were detected in 111/224 (49.5%) males and 49/103
(47.6%) females, p = 0.74. Immune responses were
detected in 130/249 (53%) in patients less than 64 years
old, 30/78 (38.5%) older patients (p = 0.026 by cumulative
incidence over time; p = 0.034 by Chi-squared analysis).
Age greater than 64 accounted for a 14.5 % decrease in
immune response.
Conclusion
While our study shows a measurable decline in immune
response with increasing age, a significant percentage of
elderly patients do develop immune responses to vaccina-
tion. Meanwhile, gender was not shown to affect immune
response despite evidence suggesting an immunoprotec-
tive association with female gender [3].This information
should be considered in patient selection for cancer
vaccines. In particular, elderly patients should be made
aware of this difference prior to undergoing vaccination
but should not be excluded on the basis of age.
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